(a) Geographic hyperpigmentation of the tongue associated with dark patches of oral mucosa. (b) Dotty pigmentation of the tongue.
Sir,
Oral lesions are reported in 9%-45 % of patients with systemic lupus erythematosus (SLE) and in 4%-25% of patients with discoid lupus erythematosus. 1 They can appear on the mucosa of the gum, palate, and inferior lip. Oral discoid lesions, honeycomb plaques, raised keratosis, erythema, purpura, irregular ulcers, or cheilitis are frequently reported lesions. 2 On the other hand, hyperpigmentation of the oral mucosa has not been reported as a manifestation of lupus flares.
Here, we report two cases of patients with oral mucosa pigmentation associated with SLE flares that completely resolved upon therapy.
A 35-year-old Moroccan woman presented with a two-week history of painless geographic hyperpigmentation of the tongue associated with dark patches of oral mucosa (Figure 1(a) ). Fifteen years before, she had been diagnosed with SLE because of polyarthritis associated with photosensitivity, cutaneous and mucosal pigmentation, along with high antinuclear and anti-double-stranded DNA (anti-dsDNA) antibody titers. Symptoms resolved upon corticosteroid therapy and she remained untreated during the six years prior to admission. She had never received antimalarial drugs. On examination, she had lymphadenopathy, arthritis, vespertilio, and diffuse melanonychia. Laboratory tests showed high level of serum anti-dsDNA and hypocomplementemia. Lip biopsy revealed melanin granules, an inflammatory lymphocytic infiltration, and the immunofluorescence was positive for the lupus band test. Treatment with hydroxychloroquine and prednisone led to polyarthritis and hyperpigmentation disappearance.
The second case was a 33-year-old Vietnamese man who had a two-year history of SLE. At SLE onset, symptoms were fever, lymphadenopathy, polyarthritis, mononeuritis multiplex, and renal nephritis. Also he had photosensitivity, vespertilio, and a dotty pigmentation of the tongue. All the symptoms resolved after an initial treatment with rituximab and prednisone. After 18 months, while the treatment was stopped, the patient was admitted because he complained of memory deficits. The examination revealed only a recurrence of the dotty pigmentation of the tongue (Figure 1(b) ). Laboratory tests confirmed SLE flare with hypocomplementemia, associated with renal relapse. Brain positron-emission tomography (PET) scan showed hypometabolism in both frontal lobes. Rituximab was resumed and symptoms resolved within three weeks.
Oral hyperpigmentation is a feature of several known conditions, such as Addison's disease, ethnic pigmentation, tobacco use, heavy metals exposure, malignancies, Peutz-Jegher's syndrome, neurofibromatosis, and some medications. 3 In patients with SLE treated with antimalarial drugs, the incidence of skin and mucosa pigmentation has been reported as high as 10%-25%. 4 In a recent case-control study, Jallouli et al. have reported an incidence of this adverse effect of 7%, in a mean delay of 6.1 years (range, three months-22 years), but there was no correlation with the duration or with the cumulative dose of hydroxychloroquine. 5 The lesions were generally preceded or precipitated by bruising and the biopsies showed melanin granules and hemosiderin deposits.
In our cases, none of the patients had been previously treated with antimalarials, and the complete disappearance of mucosal pigmentation upon specific therapy confirmed that these lesions were lupus specific. Thus, in the absence of another more obvious condition, oral pigmentation should be considered as a sign of lupus flare.
